For these patients and for others who contracted HIV infection with primary resistance, the subsequent iterative availability of new drug classes, including non-NRTIs and integrase-strand transferase inhibitors, essentially offered functional monotherapy against a background of complex . . .
Lenacapavir for HIV-1 — Potential Promise of a Long-Acting Antiretroviral Drug Read More »
A second major HIV prospect has been put on hold, this time from Gilead Sciences. But unlike the recent halt on Merck’s drug islatravir, which was related to a drop in trial patients’ immune cell counts, Gilead’s trial stop stems from a quality issue that could be swiftly resolved, one analyst says.
Particulate problem prompts hold on 10 Gilead studies of HIV hopeful lenacapavir Read More »
Islatravir and lenacapavir are both promising HIV treatments currently in development. The array of formulations and extended dosing options of these treatments will enable providers to better tailor a patient’s treatment to their needs.
Examining the HIV Treatment Pipeline Read More »
♦ In HTE PWH with MDR – LEN in combination with an OBR led to high rates of virologic suppression at Week 26 (81%) – LEN led to clinically meaningful increases in CD4 counts at Week 26 • While 22% had CD4
LEN displays three characteristics of an ideal long-acting agent: picomolar potency, low systemic clearance and a slow subcutaneous (SC) release
Intestinal Excretion is a Major Disposition Pathway of Lenacapavir in Rat and Dog Read More »
A Phase 1b trial that evaluated the safety, pharmacokinetics and antiviral activity of SC lenacapavir in treatment-naive or -experienced adults with HIV. This study has been completed.
Lenacapavir has been shown to be highly effective in people living with HIV who have a history of treatment with severe multi-drug resistance. LEN actively suppressed viral load when added to an ineffective regimen and in combination with optimized background therapy.
CROI 2021 Report on oral lenacapavir and probe drugs
Emergent resistance to LEN was uncommon in treatment-naïve participants receiving SC or oral LEN (0.6%, 1/157). These interim resistance findings support the ongoing evaluation of LEN for treatment and prevention of HIV.
